The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism.
Efavirenz treatment has been associated with increases in HDL-cholesterol concentrations, and the circulating levels of the drug have been related to the multidrug resistance gene 1 (MDR-1) C3435T polymorphism. The changes in the measured lipid parameters were evaluated in 59 HIV-infected patients initiating efavirenz-based treatment at baseline and at 12 months of follow-up. Efavirenz treatment increased HDL-cholesterol. The changes in concentrations appeared to be influenced by the MDR-1 gene polymorphism, in which CC > CT > TT.
Alonso-Villaverde
Carlos
C
Servei de Medicina Interna, Hospital Universitari de Sant Joan, Reus, Spain.
Coll
Blai
B
Gómez
Federico
F
Parra
Sandra
S
Camps
Jordi
J
Joven
Jorge
J
Masana
Lluis
L
D000328:Adult; D000480:Alkynes; D019380:Anti-HIV Agents / Q000009:adverse effects*; D048588:Benzoxazines; D008076:Cholesterol, HDL / Q000097:blood*; D003521:Cyclopropanes; D005260:Female; D005500:Follow-Up Studies; D019450:Genes, MDR / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D015658:HIV Infections / Q000188:drug therapy; D006801:Humans; D006937:Hypercholesterolemia / Q000139:chemically induced / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D010078:Oxazines / Q000009:adverse effects*; D011110:Polymorphism, Genetic; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D008076:Cholesterol, HDL; D003521:Cyclopropanes; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz